Biogen Inc. Securities Litigation (2020)

If you purchased a significant amount of shares of Biogen Inc. (NASDAQ: BIIB), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Biogen Inc.
Date Filed:November 13th, 2020
Sector:Health Care
Industry:Biotechnology: Biological Products (No Diagnostic Substances)
Class Start Date:October 22nd, 2019
Class End Date:November 6th, 2020

According to the Complaint, it is alleged Defendants made false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab's effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the FDA's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Biogen Inc.

 
First Identified Complaint

Victor D. Menashe, et al. v. Biogen Inc., et al.

Date Filed:November 13th, 2020
Class Period Start:October 22nd, 2019
Class Period End:November 6th, 2020
First Identified Complaint Filings
#Document TitleFiling Date